EAGLE PHARMACEUTICALS INC's ticker is EGRX and the CUSIP is 269796108. A total of 180 filers reported holding EAGLE PHARMACEUTICALS INC in Q2 2019. The put-call ratio across all filers is 2.15 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2019 | $11,000 | 0.0% | 186 | 0.0% | 0.00% | – |
| Q3 2019 | $11,000 | -21.4% | 186 | -24.7% | 0.00% | – |
| Q2 2019 | $14,000 | +16.7% | 247 | 0.0% | 0.00% | – |
| Q1 2019 | $12,000 | -7.7% | 247 | -24.2% | 0.00% | – |
| Q4 2018 | $13,000 | -7.1% | 326 | +56.0% | 0.00% | – |
| Q3 2018 | $14,000 | +7.7% | 209 | +24.4% | 0.00% | – |
| Q2 2018 | $13,000 | +225.0% | 168 | +147.1% | 0.00% | – |
| Q1 2018 | $4,000 | +100.0% | 68 | +151.9% | 0.00% | – |
| Q3 2017 | $2,000 | -91.7% | 27 | -91.0% | 0.00% | – |
| Q2 2017 | $24,000 | -4.0% | 300 | 0.0% | 0.00% | -100.0% |
| Q1 2017 | $25,000 | -47.9% | 300 | -50.0% | 0.00% | 0.0% |
| Q4 2016 | $48,000 | +14.3% | 600 | 0.0% | 0.00% | 0.0% |
| Q3 2016 | $42,000 | +82.6% | 600 | 0.0% | 0.00% | 0.0% |
| Q2 2016 | $23,000 | – | 600 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ProQuest Associates IV LLC | 3,652,284 | $302,920,000 | 91.10% |
| Hudson Executive Capital LP | 1,901,200 | $157,686,000 | 21.62% |
| JW Asset Management, LLC | 525,755 | $43,606,000 | 9.08% |
| Cormorant Asset Management, LP | 200,000 | $16,588,000 | 2.41% |
| Park West Asset Management LLC | 488,128 | $40,485,000 | 2.36% |
| Opaleye Management Inc. | 50,000 | $4,147,000 | 2.06% |
| Ranger Investment Management | 283,954 | $23,551,000 | 1.71% |
| Pier Capital, LLC | 74,732 | $6,198,000 | 1.06% |
| Bellevue Group AG | 67,700 | $5,615,000 | 0.75% |
| Orbimed Advisors | 671,000 | $55,653,000 | 0.63% |